Last updated on July 2009

Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions: Hormone Refractory Prostate Cancer
• Age: Between 18 - 100 Years
• Gender: Male

• Other:
  Subject Inclusion Criteria:
  Age >18
  Histology/cytology diagnosis of prostate cancer
  Measurable disease as identified by tumor imaging (e.g. CT, MRI) or PSA values
  greater than 1.5 ng/ml, and rising in 3 consecutive measurements.
  failure of 1st line hormone therapy (GnRH analogues)
  ECOG performance status 0-2
  Subject Exclusion Criteria:
  Concurrent use of systemic anti-neoplastic therapy
  Patients who had received systemic chemotherapy for prostate cancer.
  Patients receiving an investigational agent within the past 30 days of study entry.
  Patients with evidence of circumstances that are likely to interfere with the
  absorption of orally administrated products.
  patients with co-morbidities considered to potentially influence the outcome of
  treatment in the judgment of the investigator (life-threatening diseases such as
  heart failure)
  ECOG performance status > 2